Rheumatoid factors: What do they tell us?

Journal of Rheumatology

Volumn 29, Issue 10, 2002, Pages 2034-2040

  Newkirk, Marianna M ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RHEUMATOID FACTOR;

B LYMPHOCYTE; CELL CYCLE; CELL SECRETION; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; EDITORIAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATIC DISEASE; SJOEGREN SYNDROME; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE;

ARTHRITIS, RHEUMATOID; COMMUNICABLE DISEASES; CRYOGLOBULINEMIA; DISEASE SUSCEPTIBILITY; FEMALE; HEPATITIS C; HUMANS; IMMUNITY; MALE; RHEUMATOID FACTOR; SJOGREN'S SYNDROME;

EID: 0036790844     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (94)

1. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940;17:172-88.
2. Pike RM, Sulkin SE, Coggeshall HC. Serological reactions in rheumatoid arthritis. II. Concerning the nature of the factor in rheumatoid arthritis serum responsible for increased agglutination of sensitized sheep erythrocytes. J Immunol 1949;63:448-63.
3. Newkirk MM. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 2002;104:1-13.
4. Fehr T, Bachmann MF, Bucher E, et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 1997;185:1785-92.
5. Posnett DN, Edinger J. When do microbes stimulate rheumatoid factor? [see commentary]. J Exp Med 1997;185:1721-3.
6. Wands JR, Mann E, Alpert E, Isselbacher KJ. The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes. J Clin Invest 1975;55:930-6.
7. Gonzalez-Juanatey C, Gonzalez-Gay MA, Llorca J, et al. Rheumatic manifestations of infective endocarditis in non-addicts. A 12-year study. Medicine Baltimore 2001;80:9-19.
8. Van Snick JL, Van Roost E, Markowetz B, Cambiaso CL, Masson PL. Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes. Eur J Immunol 1978;8:279-85.
9. Hogben DN, Devey ME. Studies on rheumatoid factor: I. The effect of rheumatoid factor on the clearance of preformed immune complexes in mice. Clin Exp Immunol 1986;66:648-53.
10. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991;173:487-9.
11. Husby G, Gran JT, Johannessen A. Epidemiological and genetic aspects of IgM rheumatoid factors. Scand J Rheumatol 1988;75 Suppl:213-8.
12. Van Schaardenburg D, Lagaay AM, Otten HG, Breedveld EC. The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 1993;32:546-9.
13. Jacobsson LTH, Knowler WC, Pillemer S, et al. Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 1993;36:1045-53.
14. Newkirk MM, Lepage K, Niwa T, Rubin L. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cell Molec Biol 1998;44:1129-38.
15. Cerny EH, Farshy CE, Hunter EF, Larsen SA. Rheumatoid factor in syphilis. J Clin Microbiol 1985;22:89-94.
16. Youinou P, Mackenzie L, Katsikis P, et al. The relationship between CD5-expressing B lymphocytes and serologic abnormalities in rheumatoid arthritis patients and their relatives. Arthritis Rheum 1990;33:339-48.
17. Sowden JA, Roberts-Thomson PJ, Zola H. Evaluation of CD5-positive B cells in blood and synovial fluid of patients with rheumatic diseases. Rheumatol Int 1987;7:255-9.
18. Victor KD, Randen I, Thompson K, et al. Rheumatoid factors isolated from patients with autoimmune disorders are derived from germline genes distinct from those encoding the Wa, Po, and Bla cross-reactive idiotypes. J Clin Invest 1991;87:1603-13.
19. Youinou P, Lydyard PM. CD5+ B cells in non organ-specific autoimmune diseases: a fresh look. Lupus 2001;10:523-5.
20. Qian Y, Santiago C, Borrero M, Tedder TF. Clarke SH. Lupus-specific antiribonucleoprotein B cell tolerance in nonautoimmune mice is maintained by differentiation to B-1 and governed by B cell receptor signaling thresholds. J Immunol 2001;166:2412-9.
21. Rudolphi U, Hohlbaum A, Lang B, Peter HH, Melchers I. The B cell repertoire of patients with rheumatoid arthritis. Frequencies and specificities of peripheral blood B cells reacting with human IgG, human collagens, a mycobacterial heat shock protein and other antigens. Clin Exp Immunol 1993;92:404-11.
22. Newkirk MM, Rauch J. Monospecific but not polyreactive human hybridoma rheumatoid factors exhibit preferential binding specificities for IgG3 and IgG4. Rheumatol Int 1994;13:203-9.
23. Moynier M, Abderrazik M, Didry C, Sany J, Brochier J. The B cell repertoire in rheumatoid arthritis. Arthritis Rheum 1992;35:49-54.
24. Young CL, Adamson TC, Vaughan JH, Fox RI. Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum 1984;27:32-9.
25. Duke O, Panayi GS, Janossy G, Poulter L. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patient with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol 1982;49:22-30.
26. Murakami J, Shimizu Y, Kashi Y, et al. Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C. Hepatology 1999;30:143-50.
27. Coffman RL, Lehman DA, Rothman P. Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 1993; 54:229-70.
28. Stavnezer J. Antibody class switching. Adv Immunol 1996; 61:79-146.
29. Teitsson I, Withrington RH, Seifert MH, Valdimarsson H. Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor. Ann Rheum Dis 1984;43:673-8.
30. Moore S, Ruska K, Peters L, Olsen NJ. Associations of IgA and IgA-rheumatoid factor with disease features in patients with rheumatoid arthritis. Immunol Invest 1994;23:355-65.
31. Muller K, Oxholm P, Mier-Madsen M, Wiik A. Circulating IgA-and IgM-rheumatoid factors in patients with primary Sjogren syndrome. Correlation to extraglandular manifestations. Scand J Rheumatol 1989;18:29-31.
32. Atkinson JC, Fox PC, Travis WD, et al. IgA rheumatoid factor and IgA containing immune complexes in primary Sjogren's syndrome. J Rheumatol 1989;16:1205-10.
33. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-63
34. Wang H, Shlomchik MJ. High affinity rheumatoid factor transgenic B cells are eliminated in normal mice. J Immunol 1997; 159:1125-34.
35. Andonopoulos AP, Drosos AA, Skopouli FN, Acritidis NC, Moutsopoulos HM. Secondary Sjogren's syndrome in rheumatoid arthritis. J Rheumatol 1987;14:1098-103.
36. Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Hepatitis C virus infection mimicking primary Sjogren syndrome. A clinical and immunologic description of 35 cases. Medicine 2001;80:1-8.
37. Kassan SS, Thomas T, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;54:1027-32.
38. Board VHP. Global surveillance and control of hepatitis C. J Viral Hepatitis 1999;6:35-47.
39. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest 2001;31:628-38.
40. Zvaifler NJ. Etiology and pathogenesis of rheumatoid arthritis. In: McCarthy DJ, editor. Arthritis and allied conditions. 11th ed. Philadelphia: Lea & Febiger; 1989;659.
41. Ahmed AS, Penhale W, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 1985;121:531-51.
42. Cacoub P, Hausfater P, Musset L, Piette JC. Mixed cryoglobulinemia in hepatitis C patients. GERMIVIC. Ann Med Interne Paris 2000;151:20-9.
43. Wolfe F, Cathey MA, Roberts FK. The Latex test revisited. Rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum 1991;34:951-60.
44. Mattey DL, Gonzalez-Gay MA, Hajeer AH, et al. Association between HLA-DRB1*15 and secondary Sjogren's syndrome in patients with rheumatoid arthritis. J Rheumatol 2000;27:2611-6.
45. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467-72.
46. Martin T, Weber J-C, Levallois H, et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Blood 2000;43:908-16.
47. Katsikis PD, Youinou PY, Galanopoulou V, Papadopoulos NM, Tzioufoa AG, Moutsopoulos HM. Monoclonal process in primary Sjogren's syndrome and cross-reactive idiotype associated with rheumatoid factor. Clin Exp Immunol 1990;82:509-14.
48. Tuomi T, Aho K, Palosuo T, et al. Significance of rheumatoid factors in an eight-year longitudinal study on arthritis. Rheumatol Int 1988;8:21-6.
49. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000;39:24-9.
50. Kim JM, Weisman MH. When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum 2000;43:473-84.
51. Van Zeben D, Hazes JMW, Zwinderman AH, Cats A, van der Voort EAM, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992;51:1029-35.
52. Rau R, Herborn G, Zueger S, Fenner H. The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years. J Rheumatol 2000;27:2566-75.
53. Listing J, Rau R, Muller B, et al. HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating rheumatological Study Group. J Rheumatol 2000;27:2100-9.
54. Aman S, Paimela L, Leirisalo-Repo M, et al. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF, and CRP. A comparative 3-year follow-up study. Rheumatology 2000; 39:1009-13.
55. Kaltenhauser S, Wagner U, Schuster E, et al. Immunogenetic markers and seropositivity predict radiological progression in early rheumatoid arthritis independent of disease activity. J Rheumatol 2001;28:735-44.
56. Ohara T, Itoh Y, Itoh K. Reevaluation of laboratory parameters in relation to histological findings in primary and secondary Sjogren's syndrome. Intern Med 2000;39:457-63.
57. Cacoub P, Poynard T, Ghillan P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C. Arthritis Rheum 1999;42:2204-12.
58. Erhardt CC, Mumford P, Maini RN. Differences in immunochemical characteristics of cryoglobulins in rheumatoid arthritis and systemic lupus erythematosus and their complement binding properties. Ann Rheum Dis 1984;43:451-6.
59. Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Hepatitis C virus infection mimicking primary Sjogren syndrome. A clinical and immunologic description of 35 cases. Medicine Baltimore 2001;80:1-8.
60. Ollier WER, Silman AJ, Gosnell NG, et al. HLA and rheumatoid arthritis: an analysis of multicase families. Disease Markers 1986;4:85-98.
61. Silman AJ, Ollier B, Mageed RA. Rheumatoid factor detection in the unaffected first degree relatives in families with multicase rheumatoid arthritis. J Rheumatol 1991;18:512-4.
62. Balsa A, Barrera P, Westhovens R, et al. Clinical and immunogenetic characteristics of European multicase rheumatoid arthritis families. Ann Rheum Dis 2001;60:573-6.
63. Pease CT, Shattles W, Charles PJ, Venables PJW, Maini RN. Clinical, serological, and HLA phenotype subsets in Sjogren's syndrome. Clin Exp Rheumatol 1989;7:185-90.
64. Cacoub P, Renou C, Kerr G, et al. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 2001;44:2118-24.
65. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
66. Del Puente A, Knowler WC, Pettitt DJ, Bennett PH. High incidence and prevalence of rheumatoid arthritis in Pima Indians. Am J Epidemiol 1989;129:1170-8.
67. Jawaheer D, Thomson W, MacGregor AJ, et al. Homozygosity for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins. Arthritis Rheum 1994;37:681-6.
68. Cornelis F, Faure S, Martinez M, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci 1998;95:10746-50.
69. Del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988;31:1239-44.
70. Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991;18:1282-4.
71. Halldorsdottir HD, Jonsson T, Thorsteinsson J, Valdimarsson H. A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor. Ann Rheum Dis 2000;59:149-51.
72. Jansen LMA, van der Horst-Bruinsma IE, van Schaardenburg D, van de Stadt RJ, de Koning MHMT, Dijkmans BAC. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
73. Zulman J, Jaffe R, Talal N. Evidence that the malignant lymphoma of Sjogren's syndrome is a monoclonal B-cell neoplasm. N Engl J Med 1978;299:1215-20.
74. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000;29:296-304.
75. Anaya J-M, Liu GT, D'Souza E, Ogawa N, Luan X, Talal N. Primary Sjogren's syndrome in men. Ann Rheum Dis 1995; 54:748-51.
76. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
77. Mohsen AH, Group TH. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707-13.
78. Cicardi M, Cesana B, Del Ninno E, et al. Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat 2000;7:138-43.
79. Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990; 162:569-70.
80. Abel G, Zhang QX, Agnello V. Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum 1993;10:1341-9.
81. Invernizzi F. Type II and III mixed cryoglobulinemias, rheumatoid factors, hepatitis C virus. Semin Clin Immunol 1993;6:21-37.
82. Lunel F, Musset L. Mixed cryoglobulinemia and hepatitis C virus infection. Minerva Med 2001;92:35-42.
83. Ferri C, La Civita L, Longombardo G, Zignego AL, Pasero G. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus 1998;7:275-9.
84. Stone MJ, Fedak J. Studies on monoclonal antibodies II Immune-complex (IgM-IgG) cryoglobulinemia: the mechanism of cryoprecipitation. J Immunol 1974;113:1377-86.
85. Breitschwerdt B, Goeser T, Tissot JD, Trendenlenburg M, Sis-Kluzik JM, Andrassy K. Hepatitis virus-related and ethanol-induced chronic liver disease with or without cryoglobulins - Is there a difference concerning clinical or laboratory manifestation? Infection 1999;4/5:248-51.
86. Dispenzieri A, Gorcvic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999;13:1315-49.
87. Ferrari C, Penn A, Bertoletti A, et al. Antiviral cell-mediated immune responses during hepatitis B and hepatitis C virus infections. Recent Results Cancer Res 1998;154:330-6.
88. Lamprecht P, Moosig F, Gause A, et al. Immunological and clinical follow up of hepatitis C virus associated cryoglobulinemia vasculitis. Ann Rheum Dis 2001;60:385-90.
89. Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WL. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:1156-61.
90. Nesher G, Osborn TG, Moore TL. Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis. Clin Exp Rheumatol 1997;15:343-7.
91. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
92. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
93. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
94. Krieg AM. A role for Toll in autoimmunity. Nat Immunol 2002;3:423-4.